Ultime notizie per Xilio Therapeutics (NASDAQ:XLO) Azioni

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Xilio Therapeutics Inc

On Wednesday, Ark Invest, led by Cathie Wood, made significant trades in Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Square Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>).
The Moderna Trade
Ark Invest removed 49,922 shares of Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) on Wednesday. The trade is estimated to be worth $2.6 million, based on the latest closing price of $51.81.
This move comes after Ark Invest sold a significant amount of Moderna stock earlier in October. The company&#8217;s decision to offload over $9 million in Moderna came amidst the unveiling of Moderna&#8217;s <a href="https://www.benzinga.com/markets/24/10/41300903/cathie-woods-ark-invest-dumps-over-9m-in-moderna-stock-even-with-post-covid-plans-on-the-table">post-COVID roadmap</a>.
The Block Trade
Ark Invest sold 31,771 shares of Block on Wednesday. The trade, made through ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), is estimated to be worth $2.5 million, based on the latest closing price of $77.64.
Jack Dorsey, the CEO of Block, recently announced a fresh <a href="https://www.benzinga.com/news/24/10/41646193/block-ceo-jack-dorsey-announces-another-round-of-layoffs-at-tidal">wave of layoffs</a> at the music streaming service Tidal, which the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-focussed Block owns. This move came amidst a significant round of layoffs, with Dorsey stating that Tidal needs to function "like a startup again," necessitating a much smaller team across the organization.
Other Key Trades: 
<ul>
<li>Ark loaded up on shares of Crisper Therapeutics (CRSP) and Twist Bioscience Corp (TWST)</li>
<li>The Wood-led firm sold shares of Sofi Technologies (SOFI) and Unity Software (U). </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41767332/trumps-potential-return-to-white-house-sends-ex-president-linked-phunware-stock-upwards-during-p?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential Return To White House Sends Ex-President Linked Phunware Stock Upwards During Pre-Market Hours</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

News

Markets

ETFs

$BTC

ARKF

ARKG

ARKK

MRNA

Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped

Ripple Labs CEO Brad Garlinghouse outlined a cryptocurrency-focused agenda for President-elect Donald Trump, suggesting key changes to the SEC and pushing for clarity on Ethereum&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) status.
What Happened: Garlinghouse congratulated Trump on the presidential victory and proposed a series of actions for his first 100 days in office. 
Ripple&#8217;s top executive called for the dismissal of the current SEC head Gary Gensler, suggesting that former CFTC head Chris Giancarlo, former Acting Comptroller of the Currency Brian Brooks, or former SEC commissioner Daniel Gallagher could be suitable replacements. 
Garlinghouse also urged Trump to advance the digital asset market structure bill in the Senate by getting both Republicans and Democrats on the same side. Lastly, he sought clarity from the administration on whether Ethereum is considered a security.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41784950/pro-bitcoin-senator-cynthia-lummis-vows-to-build-a-strategic-bitcoin-reserve-as-industry-e">Pro-Bitcoin Senator Cynthia Lummis Vows To &#8216;Build A Strategic Bitcoin Reserve&#8217; As Industry Experts Laud Trump Win</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a>, Congratulations! Some fodder for your first 100-day checklist to get things moving: &#8211; Fire Gensler. Day 1, no delays. &#8211; In his place, appoint Giancarlo, Brooks, or Gallagher – they'd be massive upgrades in rebuilding the rule of law (and reputation) at the…
&mdash; Brad Garlinghouse (@bgarlinghouse) <a href="https://twitter.com/bgarlinghouse/status/1854134741089316961?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Garlinghouse&#8217;s suggestions reflect his ongoing efforts to promote pro-cryptocurrency policies. 
He previously <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41442996/brad-garlinghouse-defends-ripple-co-founders-donation-to-kamala-harris-while-top-crypto-an">emphasized</a> the importance of bipartisan support for cryptocurrency and <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41442996/brad-garlinghouse-defends-ripple-co-founders-donation-to-kamala-harris-while-top-crypto-an">backed Ripple executives </a>who donated to candidates they thought were good for the industry, regardless of the politics.
Interestingly, Ripple co-founder Chris Larsen endorsed Kamala Harris leading up to the elections, while legal head&nbsp;Stuart Alderoty made donations to Trump-supporting groups.
Ripple was locked in a nearly <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40240559/xrp-outshines-bitcoin-ethereum-to-become-biggest-daily-gainer-after-judge-imposes-125m-pen">four-year-long legal battle</a> with the SEC over the status of XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), a payment-focused cryptocurrency at the center of Ripple&#8217;s operations. 
Price Action: At the time of writing, XRP was exchanging hands at $0.5448, up 4.93% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Image via Shutterstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41786812/which-musk-company-will-propel-dogecoins-future-x-tesla-spacex-or-the-boring-company">Which Musk Company Will Propel Dogecoin&#8217;s Future — X, Tesla, SpaceX Or The Boring Company?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

$ETH

$XRP

Ripple CEO Brad Garlinghouse Proposes Crypto Blueprint For Trump's First 100 Days: 'Fire Gensler. Day 1, No Delays'

Wedbush Securities predicts Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) artificial intelligence initiatives could see major gains under a Trump presidency, despite potential headwinds for the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">broader electric vehicle sector</a>. 
What Happened: Dan Ives, a leading analyst at Wedbush Securities, projects that Donald Trump&#8216;s return to the White House could significantly boost Tesla&#8217;s AI ambitions, potentially unlocking &#8220;$1 trillion of incremental AI valuation&#8221; for the electric vehicle maker over the coming years.
However, the outlook for the broader EV industry appears mixed. Tesla CEO Elon Musk, who actively campaigned for Trump, has acknowledged that the incoming administration would likely eliminate EV subsidies and tax credits, as discussed during Tesla&#8217;s second-quarter earnings call.
&#8220;We believe Trump in the White House changes the landscape for Elon Musk and Tesla,&#8221; Ives said during an appearance on CNBC&#8217;s Squawk Street. The analyst characterized Musk&#8217;s alignment with Trump as a &#8220;major strategic bet&#8221; that could prove &#8220;very bullish for Tesla&#8217;s AI/autonomous story.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We believe Trump in the White House changes the landscape for <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> and <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a> and will start the unlock the $1 trillion of incremental AI valuation in the Tesla story in our view over the coming years <a href="https://twitter.com/SquawkStreet?ref_src=twsrc%5Etfw">@SquawkStreet</a> &#x1f525;&#x1f3c6;&#x1f402;&#x1f37f; <a href="https://t.co/nDyomh80F7">https://t.co/nDyomh80F7</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1854307652056015007?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/politics/24/11/41790636/kamala-harris-concedes-calls-for-unity-commitment-to-democracy">Kamala Harris Concedes: Calls For Unity, Commitment To Democracy</a>
Why It Matters: The firm projects Tesla&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41766869/trump-win-biggest-positive-for-elon-musks-tesla-tech-bull-says-it-could-boost-ev-gi">stock could see a $40-$50 price increase under a Trump presidency</a>, representing a potential upside of 16% to 20% based on current trading levels. Analysts attribute this positive outlook to Tesla&#8217;s established market position and manufacturing capabilities.
&#8220;We believe a Trump presidency would be an overall negative for the EV industry as likely the EV rebates/tax incentives get pulled,&#8221; Wedbush analysts wrote on Tuesday. &#8220;However, for Tesla, we see this as a potential positive with some caveats.&#8221;
Beyond Tesla, Ives anticipates significant AI initiatives that could benefit other <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41766869/trump-win-biggest-positive-for-elon-musks-tesla-tech-bull-says-it-could-boost-ev-gi">major tech players</a>, including Microsoft Corp., Amazon.com Inc., Alphabet Inc.&#8216;s Google, and Palantir Technologies Inc.
The analysis comes as Trump prepares to <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">assume office as the 47th president of the United States</a>, marking a period of potential transformation for both the technology and automotive sectors.
Price Action: Tesla Inc. showcased a standout performance on Wednesday, closing up 14.75% at $288.53, marking a significant single-day gain that brought its year-to-date rise to 16.15%. 
In contrast, key U.S.-based EV competitors struggled considerably, including Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Nio Inc. (NYSE: NIO). Rivian dropped 8.31% to $9.71, extending its challenging 2024 trajectory with a year-to-date decline of 53.98%. Nio fell 5.30% to $5.00, with a year-to-date slide of 40.62%.
Chinese EV maker Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) and leading Chinese hybrid-electric giant BYD Company (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) also experienced losses, albeit to a lesser extent. Xpeng closed down 3.98% at $12.30, while BYD dropped 4.53% to $71.93, though BYD remains a strong performer overall, up 33.95% year-to-date.
On the ETF side, Tesla&#8217;s momentum mirrored that of Simplify Volt RoboCar Disruption and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCAR#NYSE">VCAR</a>), which surged 18.48% on Tuesday. However, the broader EV sector showed mixed results, with the SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>) increasing by only 1.23%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41785495/us-treasuries-take-sharpest-plunge-in-a-year-ahead-of-fed-meeting-could-powell-adjust-stance-in-">US Treasuries Take Sharpest Plunge In A Year Ahead Of Fed Meeting: Could Powell Adjust Stance In Response To Trump?</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BYDDY

HAIL

RIVN

TSLA

Simplify Volt RoboCar Disruption and Tech ETF

VCAR

XPEV

Trump White House Could Unlock Trillion-Dollar AI Potential For Tesla, Says Dan Ives

Wednesday&#8217;s trading session saw the S&amp;P 500 and Dow Jones Industrial Average hitting record highs, driven by investor optimism following the <a href="https://www.benzinga.com/markets/asia/24/11/41768811/donald-trump-wins-47th-presidency-us-futures-up-europe-up-asia-mixed-crude-falls-and-dollar-strength">election</a> of Donald Trump as the 47th U.S. president. The S&amp;P 500 index climbed 2.5% to 5,929.04, while the Dow soared over 3.6% to 43,729.93, marking its biggest single-day gain since November 2022. The tech-heavy Nasdaq rose nearly 3% to end Wednesday&#8217;s session at 18,983.47.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Arm Holdings Plc – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)
Arm Holdings closed the day up by 2.87% at $144.68, with an intraday high of $146.06 and a low of $141.01. The company&#8217;s 52-week high and low are $188.75 and $49.82 respectively. Arm reported second-quarter revenue of $844 million, beating analyst estimates, driven by record levels of royalty revenue. The <a href="https://www.benzinga.com/news/earnings/24/11/41788528/arm-holdings-q2-earnings-revenue-beat-eps-beat-ai-creating-new-opportunities-and-more">chip designer</a> also reported adjusted earnings of 30 cents per share, surpassing analyst estimates.
Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)
Coinbase shares surged 31.11% to close at $254.31, with an intraday high of $257.68 and a low of $221.11. The company&#8217;s 52-week high and low are $283.48 and $84.3 respectively. The <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41782783/coinbase-ceo-brian-armstrong-welcomes-most-pro-crypto-congress-ever-as-end-to-gary-gensler">cryptocurrency exchange</a> is expecting to see a leadership change in the SEC as early as April or May 2025, following historical patterns.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41763941/jim-cramer-blasts-super-micro-computers-earnings-better-at-exonerating-itself-than-selling-nvidi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Blasts Super Micro Computer&#8217;s Earnings: &#8216;Better At Exonerating Itself Than Selling&#8217; Nvidia GPU</a>
Lyft Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>)
Lyft shares rose 4.35% to close at $14.40, with an intraday high of $14.53 and a low of $13.78. The company&#8217;s 52-week high and low are $20.82 and $8.93 respectively. Lyft announced new <a href="https://www.benzinga.com/markets/equities/24/11/41779428/whats-going-on-with-lyft-stock-today">autonomous vehicle partnerships</a> to offer future autonomous vehicle rides through the Lyft app, in a strategic alliance with Mobileye Global Inc.
IonQ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)
IonQ shares increased 7.2% to close at $16.45, with an intraday high of $16.83 and a low of $15.85. The company&#8217;s 52-week high and low are $18.20 and $6.22 respectively. IonQ reported <a href="https://www.benzinga.com/news/earnings/24/11/41789866/ionq-q3-earnings-revenue-beat-eps-miss-bookings-jump-on-air-force-research-contract-guidance-raise-">third-quarter financial results</a> with total revenue up 102% on a year-over-year basis, achieving $63.5 million worth of new bookings in the third quarter.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla shares jumped 14.75% to close at $288.53, with an intraday high of $289.59 and a low of $275.62. The Elon Musk-led company&#8217;s 52-week high and low are $289.59 and $138.8 respectively. Analyst Dan Ives is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41766869/trump-win-biggest-positive-for-elon-musks-tesla-tech-bull-says-it-could-boost-ev-gi">optimistic</a> about the impact of a potential Trump win on the Tesla stock.
Prepare for the day&#8217;s trading <a href="Premarket Movers &amp; News">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734887/cathie-woods-latest-shake-up-dumps-palantir-and-jack-dorseys-block-along-with-tesla-buys-amazon-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Latest Shake-up: Dumps Palantir And Jack Dorsey&#8217;s Block Along With Tesla, Buys Amazon And Meta</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

COIN

IONQ

LYFT

Arm Holdings, Coinbase, Lyft, Ionq, And Tesla: Why These 5 Stocks Are On Investors' Radars After The Elections

Leading cryptocurrencies gave a thumbs up to Donald Trump's presidential victory in anticipation of a friendlier White House.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 7:30 p.m. ET)</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>+6.15%</td>
<td>$75,185.83</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>+9.67%</td>
<td>$2,706.00</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>+8.18%</td>
<td>$0.1941</td>
</tr>
</tbody>
</table>
</figure>
What Happened: Bitcoin bettered its previous all-time high established in March with a handsome rally that pushed it above $75,000 for the first time.
The apex cryptocurrency's fourth-quarter gains increased to 18.74%, with history showing average returns of 83%.
Ethereum jumped to levels last seen in late August, while Dogecoin spiked over 8%.
Ethereum also encountered heavy sell-offs, while Dogecoin outperformed the market with over 8% gains in the last 24 hours.
Bearish leveraged traders witnessed a bloodbath, with nearly $400 million in short positions getting wiped out in the last 24 hours.
Bitcoin's Open Interest surged 9.30%, indicating a significant rise in speculative interest. Most top traders on the cryptocurrency exchange Binance leaned toward bullish positions, as the Binance Top Trader Long/Short Ratio was 1.48 as of this writing.
Market sentiment snowballed to "Extreme Greed," as per the Cryptocurrency Fear and Greed Index, raising concerns of a correction.
Top Gainers (24-Hours)
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 7:30 p.m. ET)</td>
</tr>
<tr>
<td>First Neiro On Ethereum (NEIRO)</td>
<td>+59.56%</td>
<td>$0.002222</td>
</tr>
<tr>
<td>Ethena (ENA)</td>
<td>+36.18%</td>
<td>$0.5015</td>
</tr>
<tr>
<td>Bittens (TAO)</td>
<td>+32.70%</td>
<td>$1.32</td>
</tr>
</tbody>
</table>
</figure>
The global cryptocurrency stood at $2.47 trillion, following an increase of 5.55% in the last 24 hours.
Stocks erupted in a frenzy on Wednesday. The Dow Jones Industrial Average jumped 1,508.05 points, or 3.57%, to a record close at 43,729.93.&nbsp;
The S&amp;P 500 lifted 2.53% to end at 5,929.04, while the tech-focused Nasdaq Composite gained 2.95% to close at 18,983.47. Both of these indexes notched a new record as well.
The benchmarks were helped by a 14.8% rally in the shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), the tech behemoth whose CEO Elon Musk geared up for a potential role in the new Trump administration.
Trump-owned Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) also lifted nearly 6% during the session.
See More: <a href="https://www.benzinga.com/money/best-crypto-scanners">Best Cryptocurrency Scanners</a>
Analyst Notes: Popular on-chain analytics firm CryptoQuant noted that Bitcoin was still not overvalued, despite leaping to new highs.
"The MVRV ratio shows BTC is still far from peak levels. The price is also close to the purchase cost of traders, indicating it's not overheated. This hints at a potential for further growth," the firm said in an X post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin's new all-time high doesn't mean it's overvalued relative to its cost basis. The MVRV ratio shows <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> is still far from peak levels. The price is also close to the purchase cost of traders, indicating it's not overheated. This hints at a potential for further growth. <a href="https://t.co/xeeDdipN9O">pic.twitter.com/xeeDdipN9O</a>
&mdash; CryptoQuant.com (@cryptoquant_com) <a href="https://twitter.com/cryptoquant_com/status/1854187011168420126?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Arthur Azizov, CEO of cryptocurrency payment provider B2BINPAY, said in a statement to Benzinga that Bitcoin might correct sharply by the end of this week or early next.
"The Bitcoin chart shows significant uncovered liquidity below the current price, while liquidity above has already been absorbed, indicating that a downward movement is needed to support sustainable future growth. Additionally, the Federal Reserve's rate announcement on Thursday is expected to bring further price volatility," Azizov added.
Furthermore, he expected BTC to range between $80,000 and $90,000 by year-end.
Photo by Avi Rozen on Shutterstock
Read Next:&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778985/the-bitcoin-act-of-2024-is-a-significant-proposal-will-it-redefine-us-crypto-regulation">The BITCOIN Act Of 2024 &#8216;Is A Significant Proposal&#8217; — Will It Redefine US Crypto Regulation?</a></li>
</ul>

Movers

Trading Ideas

$DOGE

Bitcoin, Ethereum, Dogecoin Slingshot To The Moon After Trump Victory But 'Sharp' Correction Might Be In Store: Analyst Views BTC Between $80-90K By End Of Year

The social media account of&nbsp;Peter Beck, CEO of&nbsp;Rocket Lab USA Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), was hacked, leading to a fraudulent post about a new crypto-based token.
What Happened: On Wednesday, the unauthorized post from Beck&#8217;s X, formerly Twitter account, promoted a new Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-based token to fund space-related projects, reported Reuters.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06202850/Screenshot-2024-11-07-at-6.54.15%E2%80%AFAM-935x1024.png" alt="" class="wp-image-634096" /><figcaption class="wp-element-caption">Screenshot from Peter Back&#8217;s compromised X Account</figcaption></figure>
At the time of writing, the above post from Back&#8217;s account was removed.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
A major player in the small satellite launch market valued at $6.5 billion, Rocket Lab was working with the platform to regain control of the account.&nbsp;
&#8220;Peter&#8217;s account has been compromised,&nbsp;so this is not an&nbsp;official tweet. We are working&nbsp;with X to restore it,&#8221;&nbsp;a company spokesperson confirmed in an email to Reuters.
Rocket Lab did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comments.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: On Tuesday, Rocket Lab announced the successful launch of its <a href="https://www.benzinga.com/news/24/11/41750137/whats-going-on-with-rocket-lab-stock-tuesday">54th Electron mission</a>, deploying a single satellite to Low Earth Orbit for a confidential commercial customer.
Last month, Rocket Lab&#8217;s shares saw a boost following the Joe Biden administration&#8217;s <a href="https://www.benzinga.com/government/24/10/41392734/rocket-lab-stock-climbs-as-biden-administration-plans-to-ease-export-restrictions-on-space-companies">plans to ease export restrictions</a> on U.S. commercial space companies.
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41706934/how-to-master-ios-18s-control-center-tips-to-reset-and-customize-your-iphones-quick-access-hub?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Master iOS 18&#8217;s Control Center: Tips To Reset And Customize Your iPhone&#8217;s Quick Access Hub</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

Media

RKLB

Rocket Labs CEO Peter Beck's X Account Hijacked By Crypto Scammers

Robert Kennedy Jr. has disclosed President-Elect Donald Trump&#8217;s three-fold directive to him, aimed at transforming the nation&#8217;s health landscape.
What Happened: On Wednesday, Kennedy Jr. took to X to share the tasks Trump has assigned to him. He wrote that Trump asked him to do three things: clean up corruption in health agencies, restore evidence-based science, and end the chronic disease epidemic to make America healthy again.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Trump has asked me to do three things: 1. Clean up the corruption in our government health agencies. 2. Return those agencies to their rich tradition of gold-standard, evidence-based science. 3. Make America Healthy Again by ending the chronic disease epidemic. <a href="https://t.co/WHMOsD0CiI">pic.twitter.com/WHMOsD0CiI</a>
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1854281809464529384?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41741814/walgreens-agrees-to-100-million-settlement-over-alleged-deceptive-pricing-of-generic-drugs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs</a>
This announcement comes after Trump&#8217;s previous pledge to give Kennedy <a href="https://www.benzinga.com/news/24/10/41565423/trump-says-robert-kennedy-jr-can-run-wild-on-health-and-food-im-going-to-let-him-go-wild-on-the-medi">full authority over health</a>, food, and medicine issues if he secures a second term. The former President had expressed his intent to allow Kennedy to &#8220;run wild&#8221; on these matters, with the exception of oil.
Kennedy Jr. is known for his contentious views on vaccines and has also been know to speak out regularly on food additives. In the aftermath of the election, shares of pharmaceutical companies, particularly those associated with the COVID-19 vaccine, have slid.
On Wednesday Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Modern Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stocks hovered near their 52-week lows of $25.20 and $49.60 respectively. For the day, PFE ended 2.2% lower at $27.36, while MRNA dropped 2.8% to $51.81. The iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) fell 0.5% to $68.39 in a similar period.
Why It Matters: Kennedy&#8217;s new role and the tasks assigned to him align with Trump&#8217;s earlier statements. In a recent interview, Trump showed tentative support for Kennedy&#8217;s plan to <a href="https://www.benzinga.com/news/24/11/41704387/robert-kennedy-jr-says-he-will-advise-all-us-water-systems-to-remove-fluoride-on-day-1-of-trump-admi">remove fluoride from water</a>, a move aimed at improving public health. Kennedy, known for his health-related advocacies, stated that his administration would encourage all U.S. water systems to eliminate fluoride on its first day in office.
Furthermore, Kennedy had previously disclosed that he might be appointed by Trump to select leaders for <a href="https://www.benzinga.com/news/24/09/40931166/robert-kennedy-jr-trump-wants-him-to-help-pick-cdc-fda-and-nih-leaders-unravel-the-capture-of-agenci">key public health agencies</a>, including the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. This latest announcement seems to confirm his involvement in these agencies, marking a significant shift in the country&#8217;s health policies.
Image via Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Health Care

General

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.

STOCK MOVES UP OVER 4% ON DAY
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="696" height="829" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/06212242/Screen-Shot-2024-11-06-at-4.19.30-PM.png" alt="" class="wp-image-3023" style="width:auto;height:450px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/06212242/Screen-Shot-2024-11-06-at-4.19.30-PM.png 696w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/06212242/Screen-Shot-2024-11-06-at-4.19.30-PM-252x300.png 252w" sizes="(max-width: 696px) 100vw, 696px" /></figure>
First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:00 AM on November 6th, a significant trading signal occurred for First Citizens BancShares, Inc. as it demonstrated a Power Inflow at a price of $2171.52. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in FCNCA&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in FCNCA&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for FCNCA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $2171.52. The returns on the High price ($2275.99) and Close price ($2266.39) after the Power Inflow were respectively 4.8% and 4.4%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

FCNCA

Tradepulse Power Inflow Alert: First Citizens Bancshares Inc. Rises Over 100 Points After Signal

NDRA

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SQQQ

Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) sees FY2024 sales of $2.650 billion-2.850 billion.

Guidance

Everus Construction Group Sees FY2024 Sales $2.650B-2.850B

Tapping into voters&#8217; dissatisfaction with the economy, among other issues, Donald Trump won the popular vote in the presidential <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">election</a> on Tuesday night. 
Meanwhile, bond traders on Wall Street dubbed &#8220;bond vigilantes&#8221; remain worried about long-term economic prospects under a Trump presidency.
What Are Bond Vigilantes?: A bond vigilante is an investor who protests against inflationary monetary or fiscal policies by selling bonds. This, in turn, increases bond yields which can force politicians&#8217; hand against inflationary policies.
Inflation necessitates increases in interest rates which erode the value of bonds.
Yields increased sharply during the Clinton administration during a period of concern over fiscal spending. The administration subsequently reduced the federal deficit, leading yields to recede.
The Trump Campaign: Trump&#8217;s 2024 campaign focused on populist economic policies, including high tariffs on imported goods and a possible elimination of the income tax. Experts say that Trump&#8217;s agenda would spur economic growth but would <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39131503/ex-treasury-secretary-larry-summers-warns-trumps-re-election-may-push-mortgage-rate">be highly inflationary</a>.
Trump ran on tax cuts in his 2016 election win and enacted the Tax Cuts and Jobs, which <a href="https://taxfoundation.org/blog/tcja-corporate-tax-economic-effects/">boosted</a> corporate investment but <a href="https://www.benzinga.com/government/24/06/39462030/trump-added-nearly-two-times-more-to-the-national-debt-than-biden-while-in-office-new-report">added $1.9 trillion</a> to the U.S. national debt.
If Trump follows through on his policy commitments — which could be likely with a solidly red Senate and a yet-to-be-called House of Representatives — the fiscal deficit will balloon.
The Bond Market Reacts: The bond market quickly reacted to Trump&#8217;s win. The benchmark 10-year Treasury yield rose to 4.479%, its highest mark since July.
Much of Trump&#8217;s win was already priced in by the markets —10-year yields are up over seven-tenths of a percentage point since early September.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41785495/us-treasuries-take-sharpest-plunge-in-a-year-ahead-of-fed-meeting-could-powell-adjust-stance-in-">US Treasuries Take Sharpest Plunge In A Year Ahead Of Fed Meeting: Could Powell Adjust Stance In Response To Trump?</a></li>
</ul>
This image was created using artificial intelligence MidJourney.

Bonds

Return Of The Bond Vigilante: Yields Skyrocket After Trump Win

Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. The company reported quarterly sales of $175.021 million which beat the analyst consensus estimate of $173.365 million by 0.96 percent. This is a 12.94 percent increase over sales of $154.967 million the same period last year.

Earnings

Earnings Beats

QTWO

Q2 Holdings Q3 2024 GAAP EPS $(0.20) Beats $(0.22) Estimate, Sales $175.021M Beat $173.365M Estimate

Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) reported quarterly losses of $(2.22) per share. The company reported quarterly sales of $1.089 billion which missed the analyst consensus estimate of $1.126 billion by 3.29 percent. This is a 3.29 percent decrease over sales of $1.126 billion the same period last year.

Earnings Misses

LILAK

Liberty Latin America Q3 2024 GAAP EPS $(2.22), Sales $1.089B Miss $1.126B Estimate

In the aftermath of the 2024 presidential election, Sen. Bernie Sanders (I-Vt.) has publicly criticized the Democratic Party&#8217;s handling of working-class issues.
What Happened: A statement released on Tuesday by Sanders expressed his disappointment with the Democratic Party&#8217;s neglect of the working class, which he believes has led to their abandonment of the party. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It should come as no great surprise that a Democratic Party which has abandoned working class people would find that the working class has abandoned them. While the Democratic leadership defends the status quo, the American people are angry and want change. And they're right. <a href="https://t.co/lM2gSJmQFL">pic.twitter.com/lM2gSJmQFL</a>
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1854271157135941698?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;It should come as no great surprise that a Democratic Party which has abandoned working class people would find that the working class has abandoned them.&#8221;
Sanders highlighted the increasing income and wealth inequality in the U.S., with 60% of Americans living paycheck to paycheck. He also criticized the country&#8217;s healthcare system and its continued financial support for the Netanyahu government.
&#8220;Unbelievably, real, inflation-accounted-for weekly wages for the average American worker are actually lower now than they were 50 years ago.&#8221;
Sanders wondered if the Democratic party would actually learn any real lessons from this &#8220;disastrous campaign.&#8221; He expressed his lack of confidence in this being a learning movement for the democrats.
&#8220;In the coming weeks and months those of us concerned about grassroots democracy and economic justice need to have some very serious political discussions,&#8221; said Sanders.
In a post on X, on Wednesday, Sanders said, &#8220;While the Democratic leadership defends the status quo, the American people are angry and want change.&#8221; He said &#8220;They&#8217;re right.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/11/41733899/trump-woos-muslim-voters-says-hes-building-the-biggest-and-broadest-peace-coalition-kamala-and-her-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Woos Muslim Voters, Says He&#8217;s &#8216;Building The Biggest And Broadest&#8217; Peace Coalition: &#8216;Kamala And Her</a>
Why It Matters: Sanders&#8217; criticism comes in the wake of the 2024 presidential election, where Donald Trump <a href="https://www.benzinga.com/markets/asia/24/11/41768811/donald-trump-wins-47th-presidency-us-futures-up-europe-up-asia-mixed-crude-falls-and-dollar-strength">won over Democratic rival</a> Kamala Harris. The election results sparked an &#8220;everything rally&#8221; on Wall Street, with major U.S. equity indices surging to record highs. This was largely due to investor optimism over anticipated favorable tax policies under the Trump administration.
Before the election, Sanders had <a href="https://www.benzinga.com/news/24/10/41642184/bernie-sanders-says-trumps-plan-to-eliminate-all-income-taxes-is-insane-economics-will-trigger-the-b">criticized Trump&#8217;s proposal to eliminate all income taxes</a>, describing it as &#8216;insane economics&#8217; that would disproportionately benefit the wealthy. He also <a href="https://www.benzinga.com/news/24/10/41590597/bernie-sanders-explains-why-he-will-vote-for-kamala-harris-even-though-he-disagrees-with-her-stance">expressed his disagreement with Kamala Harris&#8217; stance on the Gaza war</a>, but still pledged his vote for her.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Bernie Sanders Says 'American People Are Angry And Want Change' And 'They're Right' — Democrats Have Abandoned The Working Classes

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and raises the price target from $4 to $4.5.

Price Target

Analyst Ratings

ABUS

Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $4.5

Hurricane Rafael made landfall in Cuba as a Category 3 storm on Wednesday. Here's a look at what stocks could be affected as the hurricane takes <a href="https://www.benzinga.com/markets/equities/24/10/41240852/back-to-back-hurricanes-batter-floridas-insurance-market-stocks-to-watch">aim at the Gulf of Mexico. </a>
What To Know: According to <a href="https://www.foxweather.com/weather-news/tracking-hurricane-rafael-us-gulf-of-mexico-caribbean">a report</a> from Fox Weather, Hurricane Rafael made landfall in the Cuban province of Artemisa with sustained winds of 115 miles per hour, making it a Category 3 hurricane. The storm is expected to enter the Gulf of Mexico on Wednesday night and residents along the coast from Florida to Texas will be watching the storm's path.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
What To Watch: Hurricanes affect people, homes and companies in their paths and spread wide-reaching effects on various sectors and industries. Insurance companies see an influx of claims resulting from damage to property and vehicles. Homes will have to be repaired and rebuilt driving sales of lumber, windows and sheetrock higher. Power outages cause consumers to seek portable generators as an alternative way to power their homes.&nbsp;
Home improvement stores like Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) and Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) could see a pop in sales as people rush to secure their homes before the storm and repair damage after. 
Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) designs and manufactures standby generators and portable generators and often sees its shares rise before and after major weather events. 
Shares of insurance companies tend to drop after natural disasters and investors may want to keep an eye on Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), Travelers Companies, Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) and Chubb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) in the days and weeks following a potential landfall from Hurricane Rafael. 
Power companies including Duke Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) and Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) could face increased labor costs and additional costs to repair infrastructure after the storm.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Hurricane Rafael as a tropical storm, 11.5.2024. Courtesy the NOAA/Public Domain

GNRC

Hurricane Rafael Hits Cuba As Category 3 Storm: Stocks To Watch As Storm Heads Into Gulf Of Mexico

Jones Trading analyst Matthew Erdner maintains Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) with a Buy and maintains $12.5 price target.

AOMR

Jones Trading Maintains Buy on Angel Oak Mortgage REIT, Maintains $12.5 Price Target

ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares were down 2.22% to $661.43 at market close Wednesday following news of Donald Trump's victory in the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 U.S. presidential election</a>.
Trump&#8217;s return to office, coupled with a Republican majority in the Senate and a lead in the House of Representatives, has raised concerns over renewed trade tensions and the possibility of aggressive tariffs.
What To Know: During his campaign, Trump proposed a 60% tariff on Chinese goods, along with a universal 10% tariff on all imports to the U.S. This policy direction is worrying for global technology companies, including ASML, as its advanced lithography machines are essential to semiconductor production worldwide.
ASML's products are already impacted by U.S.-China trade policies, given the semiconductor industry's reliance on complex international supply chains. ASML, which is headquartered in the Netherlands, sells its equipment globally, including to Chinese companies — a significant revenue stream now facing increased uncertainty.
Read Also: <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">How Did S&amp;P 500 Sectors Perform During Trump&#8217;s First Term? Could This Time Be Different?</a>
What Else: The potential for additional restrictions on U.S. companies doing business with Chinese firms under Trump's administration could also hurt ASML's business indirectly. If U.S.-based tech giants face hurdles in the Chinese market, their demand for advanced lithography machines from ASML may diminish. 
Additionally, rising economic and political tensions could fuel an ongoing shift in tech supply chains as companies reassess global expansion plans and sourcing, a trend that could complicate ASML's growth strategy over the long term.
Market analysts at JPMorgan Chase &amp; Co underscored Trump's proposed tariffs are likely to be "a direct headwind to global technology trade," which could hit companies like ASML more acutely than other sectors.
Given ASML's reliance on global market stability and free trade to maintain its dominance in semiconductor manufacturing equipment, the return of protectionist trade policies under Trump's administration raises significant concerns about the company's medium- to long-term outlook.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ASML has a 52-week high of $1,110.09 and a 52-week low of $633.80.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41784504/trumps-win-sends-indices-to-record-highs-financials-small-caps-surge-bitcoin-tops-75-000-w">Trump&#8217;s Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo: Shutterstock

Global

ASML

What's Going On With ASML Holding Stock?

Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 300 percent. The company reported quarterly sales of $21.321 million which missed the analyst consensus estimate of $21.384 million by 0.29 percent. This is a 3.90 percent increase over sales of $20.520 million the same period last year.

USIO

Usio Q3 2024 Adj. EPS $(0.02) Misses $0.01 Estimate, Sales $21.321M Miss $21.384M Estimate

Xilio Therapeutics reports Q4 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the fourth quarter of 2023.<ul><li>Xilio Therapeutics reported earnings per share of -64 cents. This was above the analyst estimate for EPS of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/xlo-stock-earnings-xilio-therapeutics-for-q4-of-2023/">XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

With the rapidly growing demand for personalized medicine, innovative solutions, and recent developments like AI in drug discovery, the biotech industry's prospects appear robust. Thus, quality biotech stocks Vertex Pharmaceuticals (VRTX), SIGA Technologies (SIGA), and Gilead Sciences (GILD) could be ideal candidates to buy now. Read more… Fostered by rapid technological advancements and evolving industry dynamics, the biotech industry is well-positioned to experience growth and expansion. The increasing M&amp;A activities and collaboration are driving the market's prospects.
Considering the industry's bright outlook, it could be wise to invest in fundamentally sound biotech stocks Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), SIGA Technologies Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>), and Gilead Sciences Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) for potential gains.
Increasing technological advancements and shifting market dynamics are transforming the biotechnology industry. Trends like surging AI applications, RNA technology sophistication, continued growth in the CRISPR sector, and the growing <a href="https://www.labiotech.eu/in-depth/biotech-trends-2024/">merger and acquisition (M&amp;A)</a> activities are boosting the market.
The increasing M&amp;A activities strongly favor the industry involving strategic alliances, big pharma companies acquiring some larger biotech and partnering activities.
The global biotechnology market is estimated to reach $5.81 trillion by 2033, growing at a <a href="https://www.visionresearchreports.com/biotechnology-market/37875">notable CAGR of 14%</a>. Factors attributable to the industry growth include new avenues for drug discovery, personalized medicine, and agricultural improvements, backed by investment in biotechnology and accelerated innovation.
Further, the industry remains optimistic about a recovery in biotech funding despite a decline in venture financing and macroeconomic pressures. Recent developments, such as new approvals as the first <a href="https://www.marketsandmarkets.com/blog/HC/The-Global-Biotechnology-Industry-Outlook-2024">CRISPR gene therapy</a>, are propelling the industry. In 2024, the launch of up to 21 cell therapies and 31 gene therapies is projected.
Also, biotech companies are increasingly <a href="https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html">emphasizing Artificial Intelligence (AI)</a>. It accelerates research by optimizing experiments, enabling virtual screening, leading to faster detection, and more. The global AI in drug discovery market is expected to be valued at $4.90 billion by 2028, growing at a CAGR of 40.2%. 
With these encouraging trends in mind, let's delve into the fundamentals of the three top <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, beginning with the third choice.
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that engages in developing and commercializing therapies for treating cystic fibrosis (CF). The company markets TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. It sells its products to specialty pharmacies and retail pharmacies or pharmacy chains, hospitals, and clinics.
On April 10, 2024, VRTX and Alpine Immune Sciences, Inc. (<a href="https://stocknews.com/stock/ALPN/">ALPN</a>), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, entered into a definitive agreement under which VRTX will acquire Alpine for $65 per share or around $4.9 billion in cash.
The strategic acquisition of Alpine should align well with VRTX's objective of applying scientific innovation and creating transformative medicines targeting serious diseases. Alpine's lead product Povetacicept exhibits potential as a ‘pipeline-in-a-product' and its protein engineering and immunotherapy expertise will help augment VRTX's toolbox and capabilities.
On April 1, 2024, VRTX announced that inaxaplin (VX-147) advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), to compare a 45 mg once daily oral dose with a placebo. Also, the trial has now been expanded to include adolescents with AMKD ages 10 to 17 years.
When successfully approved, inaxaplin has significant potential to transform the care of AMKD and enhance patients' lives.
Also, on March 21, 2024, VRTX announced the FDA clearance of an Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector targeting the underlying cause of autosomal dominant polycystic kidney disease (ADPKD).
During the fourth quarter that ended December 31, 2023, VRTX's net product revenues rose 9.3% year-over-year to $2.52 billion. Its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew marginally from the year-ago value to $1.15 billion. The company's non-GAAP net income came in at $1.10 billion or $4.20 per common share, indicating increases of 12.1% and 11.7% from the prior year's quarter, respectively.
As of December 31, 2023, the company's total assets stood at $22.73 billion, compared to $18.15 billion as of December 31, 2022.
As per the company's full-year 2024 financial guidance, VRTX expects its total product revenue to be between $10.55 billion and $10.75 billion.
Street expects VRTX's revenue and EPS for the first quarter (ended March 2024) to increase 8.5% and 33% year-over-year to $2.58 billion and $4.06, respectively. Furthermore, the company has topped the consensus EPS estimates in all four trailing quarters, which is impressive.
Over the past six months, VRTX's stock has surged 9.6%. It gained 23.2% over the past year to close the last trading session at $400.23.
VRTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, which translates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
VRTX has a B grade for Value, Sentiment, and Quality. It is ranked #10 out of 361 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have VRTX's ratings for Growth, Momentum, and Stability. Get all VRTX ratings <a href="https://stocknews.com/stock/VRTX/">here</a>.
Stock #2: SIGA Technologies Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>)
SIGA is a commercial-stage pharmaceutical company that emphasizes health security related markets. The company's lead product includes TPOXX, an oral formulation antiviral drug for treating human smallpox disease caused by the variola virus.
On March 12, 2024, SIGA's board of directors declared a special cash dividend of $0.60 per share on its common stock. This represents an increase of $0.15 per share, or 33%, over the June 2023 special dividend, reflecting the company's robust capital structure and ability to provide stable growth in the long run.
The dividend was paid on April 11, 2024, to shareholders of record at the close of business on March 26, 2024.
On October 23, 2023, SIGA announced the creation of a joint procurement mechanism by the European Commission's DG HERA (Health Emergency Preparedness and Response Authority) under which 13 participating countries from the European Union and the European Free Trade Association could efficiently order oral TPOXX.
For the fiscal year that ended December 31, 2023, SIGA's total revenues increased 26.3% year-over-year to $139.92 million, and its operating income grew 95.8% from the prior period to $83.62 million. The company's net income and EPS of $68.07 million and $0.95 indicate growths of 100.8% and 106.5% year-over-year, respectively.
In addition, as of December 31, 2023, the company's cash and cash equivalents were $150.14 million versus $98.79 million as of December 31, 2022.
Analysts expect SIGA's revenue and EPS for the current fiscal year (ending December 2024) to grow 36.2% and 24.2% year-over-year to $190.60 million and $1.18, respectively.
Shares of SIGA have gained 89.9% over the past month and 66.2% over the past six months to close the last trading session at $9.21.
SIGA's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. 
The stock has an A grade for Value, Growth, and Quality. Within the Biotech industry, SIGA is ranked #7 of 361 stocks.
<a href="https://stocknews.com/stock/SIGA/">Click here</a> to access additional ratings of SIGA for Momentum, Sentiment, and Stability.
Stock #1: Gilead Sciences Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs internationally. The company provides products like Biktarvy, Genvoya, Descovy, and Odefsey for the treatment of HIV/AIDS, Veklury for COVID-19, and Epclusa for viral hepatitis.
On March 28, 2024, GILD announced the FDA approval of the supplemental new drug application for Vemlidy&#xAE; (tenofovir alafenamide) for treating chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older and weighing at least 25 kg with compensated liver disease.
The expanded indication for Vemlidy is a testament to the therapy's safety, tolerability, and efficacy profile, and it can potentially help many patients.
On the same day, GILD and Xilio Therapeutics, Inc. (<a href="https://stocknews.com/stock/XLO/">XLO</a>), a clinical-stage biotechnology company, entered into an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. The IL-12 program has the potential to treat a broad range of tumor types.
Under the agreement, Xilio granted GILD an exclusive global license to develop and commercialize IL-12, and Xilio will receive $43.5 million in upfront payments. The tumor-activation platform complements GILD's clinical development program in difficult-to-treat cancers and will expand its focus in immuno-oncology.
On March 22, GILD acquired CymaBay Therapeutics, Inc. (<a href="https://stocknews.com/stock/CBAY/">CBAY</a>) for nearly $4.3 billion in total equity value. The addition of CymaBay's investigational lead product candidate, seladelpar, includes pruritus and aligns with GILD's existing liver portfolio and its long-standing commitment to offering transformational medicines to patients.
GILD reported total revenues of $7.12 billion during the fourth quarter, which ended December 31, 2023. The company's non-GAAP operating income grew 1.5% from the year-ago value to $2.74 billion. Non-GAAP net income attributable to GILD and non-GAAP EPS came in at $2.16 billion and $1.72, up 2.6% and 3% year-over-year, respectively.
In addition, the company's cash, cash equivalents, and marketable debt securities stood at $8.43 billion as of December 31, 2023, compared to $7.63 billion as of December 31, 2022.
As per the fiscal full-year 2024 guidance, GILD expects total product sales of $27.1 billion-$27.5 billion and its non-GAAP EPS is expected between $6.85 and $7.25.
Street expects GILD's revenue for the second quarter (ending June 2024) to increase 2.8% year-over-year to $6.79 billion, while its EPS for the same quarter is expected to grow 27.2% year-over-year to $1.70. Moreover, the company has surpassed the consensus revenue estimates in each of the trailing four quarters.
Shares of GILD have plunged 9.3% over the past month to close the last trading session at $68.65.
GILD's POWR Ratings reflect its bright prospects. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. 
The stock has an A grade for Value and a B for Quality. GILD is ranked #5 of 361 stocks in the same industry.
<a href="https://stocknews.com/stock/GILD/">Click here</a> to access additional ratings of GILD for Momentum, Growth, Sentiment, and Stability.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
VRTX shares were trading at $398.49 per share on Friday morning, down $1.74 (-0.43%). Year-to-date, VRTX has declined -2.06%, versus a 8.23% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Dutta</h2> <img src='https:/wp-content/uploads/2021/08/Anushka-Dutta_Headshot_3.jpg' style="float:left; padding:5px;width:125px;">Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.<a href="https://stocknews.com/authors/?author=anushka-dutta">More...</a>The post <a href=https://stocknews.com/news/vrtx-gild-siga-alpn-xlo-cbay-3-biotech-stocks-to-invest-in-right-now-for-long-term/>3 Biotech Stocks to Invest In Right Now for Long-Term Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks to Invest In Right Now for Long-Term Gains

Xilio Therapeutics GAAP EPS of -$0.62

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the first quarter of 2024.<ul><li>Xilio Therapeutics reported earnings per share of -59 cents. This was below the analyst estimate for EPS of -11 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/xlo-stock-earnings-xilio-therapeutics-for-q1-of-2024/">XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024

Xilio Therapeutics (XLO) has provided an update. Xilio Therapeutics, Inc. has expanded its Board of Directors to nine members, welcoming James Shan...

Xilio Therapeutics Enhances Board with Two New Directors

Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the second quarter of 2024.<ul><li>Xilio Therapeutics reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $2.36 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xlo-stock-earnings-xilio-therapeutics-for-q2-of-2024/">XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO – Research Report) yesterday. The company's shares closed yesterday ...

TD Cowen Remains a Buy on Xilio Therapeutics (XLO)

ALPN

CBAY

GILD

HOWL

MDNAF

SIGA

VRTX

Financing

Press Releases

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Opinion

Thinking about buying stock in RPM International, Xilio Therapeutics, KULR Technology, Torrid Holdings, or IGM Biosciences?

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Management

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Comments

Xilio Therapeutics

Notizie

Ultime notizie per Xilio Therapeutics (NASDAQ:XLO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO